Flotek Industries

FTKNYSEUSD

THESIS ALERT

Email me when the FTK thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$25.47
−$0.51 (−1.96%)Today 1M −4.93%

Updated Nov 10, 4:00 PM ET · Regular session · May be delayed

—
Source valuation snapshot. Not a live recalculation.
—
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
—
Diluted earnings per share from the latest filed annual.
$25.98
Prior regular-session close from the quote source.
$24.79–$25.94
Regular-session low and high so far today.
201.7K
Regular-session shares traded · Nov 10, 4:00 PM ET.
Feb 2 projected
Projected for 2027-02-02 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$13.19–$39.67
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own FTK if its differentiated chemistry, analytics and new power assets become recurring, cash-paying customer solutions rather than a ProFrac-related contract-fee story.

FTK price history

LATEST PRICE$25.47TODAY−$0.51 (-1.96%)
FTK -2.11%S&P 500 -3.68%Since first plotted close
4 hours

Loading recent earnings…

INVESTMENT THESIS

What must happen next

5 MATERIAL PROPOSITIONS
  • Customers continue choosing Flotek’s optimized chemistry because it improves well economics and environmental performance enough to matter versus commodity chemical alternatives.StrengtheningMateriality: High

    FY2025 annual GAAP revenue was $237.3 million, up from $187.0 million in FY2024. If this holds, revenue growth reflects real customer pull; if it breaks, Flotek becomes a more cyclical, lower-multiple chemical supplier.

    Watch: ProFrac or other large pressure pumpers switch to internally sourced or competing chemistry and reduce Flotek purchase volumes.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP revenue was $237.3 million, up from $187.0 million in FY2024.

    Open source ↗
  • Flotek’s proprietary chemistries, R&I capabilities and field logistics continue to protect mix and pricing against raw-material pass-through and commodity competition.StrengtheningMateriality: High

    FY2025 annual GAAP gross_profit was $59.8 million, up from $39.4 million in FY2024 and $24.3 million in FY2023. This determines whether growth drops to the bottom line or is competed away through lower prices and higher input costs.

    Watch: Specialty-chemical competitors replicate formulations and customers rebid programs as commodity supply contracts.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP gross_profit was $59.8 million, up from $39.4 million in FY2024 and $24.3 million in FY2023.

    Open source ↗
  • The ProFrac minimum-purchase agreement remains economically valuable only if unmet volumes convert into timely cash or real product demand, not repeated offsets, renegotiations or related-party accounting gains.HoldingMateriality: Medium

    MD&A states ProFrac missed minimum purchase requirements in both FY2024 and FY2025, creating $32.4 million and $27.4 million of Contract Shortfall Fees, respectively. If the ProFrac backstop is cash-real, it reduces downside volatility; if not, reported earnings overstate owner value.

    Watch: ProFrac renegotiates or eliminates minimum purchase obligations.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    MD&A states ProFrac missed minimum purchase requirements in both FY2024 and FY2025, creating $32.4 million and $27.4 million of Contract.

    Open source ↗
  • The PWRtek mobile power acquisition creates value only if leased-back generation units earn recurring returns and reinforce Flotek’s lower-emission energy platform rather than adding leveraged equipment exposure.HoldingMateriality: Medium

    Item 1 states Flotek acquired 22 operating mobile power generation units and eight units under construction, all completed and placed into service by December 31, 2025. PWRtek can broaden the growth platform, but poor utilization or weak lease economics would turn the turnaround into a balance-sheet risk.

    Watch: ProFrac does not renew or materially reduces use of the leased-back equipment.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Item 1 states Flotek acquired 22 operating mobile power generation units and eight units under construction, all completed and placed.

    Open source ↗
  • Flotek’s small-company operating leverage benefits shareholders only if accounting profits convert into cash before working capital, equipment obligations or warrant-linked dilution consume the upside.HoldingMateriality: Medium

    FY2025 annual GAAP net_income was $30.5 million, but FY2025 annual GAAP operating_cash_flow was only $7.2 million. The difference between a high-return turnaround and a value trap is whether reported profitability funds growth without repeated external capital.

    Watch: Working-capital needs rise as chemistry volumes grow, preventing earnings from converting to cash.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP net_income was $30.5 million, but FY2025 annual GAAP operating_cash_flow was only $7.2 million.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Customers continue choosing Flotek’s optimized chemistry because it improves well economics and environmental performance enough to matter versus commodity chemical alternatives. If this holds, revenue growth reflects real customer pull; if it breaks, Flotek becomes a more cyclical, lower-multiple chemical supplier.

Flotek’s proprietary chemistries, R&I capabilities and field logistics continue to protect mix and pricing against raw-material pass-through and commodity competition. This determines whether growth drops to the bottom line or is competed away through lower prices and higher input costs.

The ProFrac minimum-purchase agreement remains economically valuable only if unmet volumes convert into timely cash or real product demand, not repeated offsets, renegotiations or related-party accounting gains. If the ProFrac backstop is cash-real, it reduces downside volatility; if not, reported earnings overstate owner value.

The PWRtek mobile power acquisition creates value only if leased-back generation units earn recurring returns and reinforce Flotek’s lower-emission energy platform rather than adding leveraged equipment exposure. PWRtek can broaden the growth platform, but poor utilization or weak lease economics would turn the turnaround into a balance-sheet risk.

Flotek’s small-company operating leverage benefits shareholders only if accounting profits convert into cash before working capital, equipment obligations or warrant-linked dilution consume the upside. The difference between a high-return turnaround and a value trap is whether reported profitability funds growth without repeated external capital.

All standing thesis claims
Original report summary

its differentiated chemistry, analytics and new power assets become recurring, cash-paying customer solutions rather than a ProFrac-related contract-fee story.

Evidence assessed Nov 4, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

BULL CASE / BEAR CASE

Bull case and bear case for Flotek Industries

Where the evidence on Flotek Industries stands: Holding on the latest evidence (Nov 4, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.

Bull case: what the evidence supports

  • Customers continue choosing Flotek’s optimized chemistry because it improves well economics and environmental performance enough to matter versus commodity chemical alternatives.

    sec.gov ↗

  • Flotek’s proprietary chemistries, R&I capabilities and field logistics continue to protect mix and pricing against raw-material pass-through and commodity competition.

    sec.gov ↗

  • The ProFrac minimum-purchase agreement remains economically valuable only if unmet volumes convert into timely cash or real product demand, not repeated offsets, renegotiations or related-party accounting gains.

    sec.gov ↗

  • The PWRtek mobile power acquisition creates value only if leased-back generation units earn recurring returns and reinforce Flotek’s lower-emission energy platform rather than adding leveraged equipment exposure.

    sec.gov ↗

  • Flotek’s small-company operating leverage benefits shareholders only if accounting profits convert into cash before working capital, equipment obligations or warrant-linked dilution consume the upside.

    sec.gov ↗

Bear case: what would count against it

  • ProFrac or other large pressure pumpers switch to internally sourced or competing chemistry and reduce Flotek purchase volumes.

    sec.gov ↗

  • Specialty-chemical competitors replicate formulations and customers rebid programs as commodity supply contracts.

    sec.gov ↗

  • ProFrac renegotiates or eliminates minimum purchase obligations.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Flotek Industries

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Flotek Industries’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. MIXED
    Reported results of operations (earnings release).

    Flotek Industries filed an SEC 8-K on 2026-11-03: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. MIXED
    Entered a material definitive agreement.

    Flotek Industries filed an SEC 8-K on 2026-09-23: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. MIXED
    Regulation FD disclosure.

    Flotek Industries filed an SEC 8-K on 2026-09-09: Regulation FD disclosure. It is a dated development that tests the current thesis.

RISKS / FALSIFIERS

What could break the thesis

  • ProFrac or other large pressure pumpers switch to internally sourced or competing chemistry and reduce Flotek purchase volumes.
  • Specialty-chemical competitors replicate formulations and customers rebid programs as commodity supply contracts.
  • ProFrac renegotiates or eliminates minimum purchase obligations.
  • ProFrac does not renew or materially reduces use of the leased-back equipment.
  • Working-capital needs rise as chemistry volumes grow, preventing earnings from converting to cash.

FTK news

Loading headlines…

FINANCIAL STATEMENTS

FTK income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

FTK: quick answers

When does Flotek Industries (FTK) report earnings next?
Flotek Industries's next results are projected for February 2, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
What is FTK's short interest?
As of October 30, 2026, 4.3M FTK shares were sold short, up 1.1% from the count before. At the stock's average daily volume that is 20 days to cover. FINRA publishes the count twice a month. FTK short interest history
Have members of Congress traded FTK?
1 trade in FTK has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed FTK trade
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.